News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
691,268 Results
Type
Article (41678)
Company Profile (295)
Press Release (649295)
Section
Business (206722)
Career Advice (2217)
Deals (35794)
Drug Delivery (82)
Drug Development (81604)
Employer Resources (174)
FDA (16081)
Job Trends (15041)
News (348728)
Policy (32921)
Tag
Academia (2609)
Africa (775)
Alliances (50017)
Alzheimer's disease (1152)
Approvals (16026)
Arizona (174)
Artificial intelligence (65)
Asia (37892)
Australia (6311)
Bankruptcy (355)
Best Places to Work (11330)
Biosimilars (61)
Biotechnology (213)
C2C Services and Suppliers (79503)
California (1547)
Canada (830)
Cancer (324)
Career advice (1848)
Cell therapy (101)
China (111)
Clinical research (63633)
Collaboration (112)
Colorado (65)
Connecticut (60)
COVID-19 (2528)
Cystic fibrosis (71)
Data (124)
Diabetes (66)
Diagnostics (6023)
Drug pricing (61)
Earnings (84213)
Employer resources (146)
Europe (81780)
Events (110343)
Executive appointments (89)
FDA (16246)
Florida (208)
Funding (93)
Gene therapy (75)
GLP-1 (512)
Government (4337)
Healthcare (18781)
Hotbed/Location (487588)
Idaho (56)
Illinois (254)
Indiana (134)
Infectious disease (2552)
Inflammatory bowel disease (88)
Interviews (369)
IPO (16314)
Job creations (3773)
Job search strategy (1582)
Kansas (97)
Layoffs (396)
Legal (7961)
Lung cancer (71)
Manufacturing (76)
Maryland (340)
Massachusetts (1308)
Medical device (13074)
Medtech (13077)
Mergers & acquisitions (19280)
Metabolic disorders (221)
Michigan (114)
Minnesota (203)
Neuroscience (1265)
New Jersey (481)
New York (481)
NextGen Class of 2024 (6598)
Non-profit (4511)
North Carolina (576)
Northern California (701)
Obesity (138)
Ohio (98)
Opinion (194)
Patents (59)
Pennsylvania (516)
People (56914)
Pharmaceutical (65)
Phase I (19782)
Phase II (28071)
Phase III (20853)
Pipeline (92)
Postmarket research (2565)
Preclinical (8452)
Press Release (71)
Rare diseases (112)
Real estate (6081)
Recruiting (68)
Regulatory (21469)
Research institute (2374)
Resumes & cover letters (370)
South America (1158)
Southern California (627)
Startups (3686)
Texas (181)
United States (7418)
Vaccines (454)
Washington State (235)
Weight loss (121)
Date
Last 7 days (469)
Last 30 days (2204)
Last 365 days (37951)
2024 (24820)
2023 (40536)
2022 (51754)
2021 (56260)
2020 (54676)
2019 (47216)
2018 (35605)
2017 (32780)
2016 (32324)
2015 (38253)
2014 (32030)
2013 (27106)
2012 (29396)
2011 (30039)
2010 (28091)
691,268 Results for "turn biotechnologies inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioCapital
HanAll Biopharma Signs Licensing Agreement with Turn Biotechnologies to Develop Novel Treatments for Eye and Ear Diseases
HanAll Biopharma Co., Ltd. has signed an exclusive licensing agreement with Turn Biotechnologies, Inc., a pre-clinical stage biopharmaceutical company focused on cellular repair through epigenetic reprogramming.
May 28, 2024
·
7 min read
Biotech Bay
Turn Biotechnologies Signs Global Licensing Agreement with HanAll Biopharma to Develop Eye and Ear Therapies
Turn Biotechnologies announced an exclusive global licensing agreement with pharmaceutical manufacturer HanAll Biopharma to develop groundbreaking medicines for the treatment of age-related eye and ear conditions.
May 28, 2024
·
4 min read
Job Trends
Difficult Market Turns More Biopharma Leaders to Fractional Roles, Say Experts
For reasons including downsizing, avoiding retirement and a tight labor market, senior-level biopharma professionals are increasingly turning to fractional roles, according to two recruitment experts.
August 28, 2024
·
4 min read
·
Angela Gabriel
Biotech Bay
Turn Biotechnologies Discussed Emerging Therapies at Aesthetic Plastic Surgery Society Meeting
Turn Biotechnologies, a developer of novel mRNA medicines and enabling technologies, presented its breakthrough research and therapies to treat age-related diseases to members of the American Society for Aesthetic Plastic Surgery, known as The Aesthetic Society.
May 7, 2024
·
2 min read
Biotech Beach
Turn Therapeutics Atopic Dermatitis Candidate Reduces Disease Severity by 57% In-Vivo
In a widely cited in-vivo model of atopic dermatitis, Turn Therapeutics’ atopic dermatitis candidate showed a dramatic reduction in disease severity versus placebo.
June 20, 2024
·
2 min read
Biotech Bay
Turn Biotechnologies’ Expands eTurna™ Delivery Platform to Solve Delivery and Targeting Issues that Challenge Industry
Turn Biotechnologies announced the expansion of its eTurna™ delivery platform that is expected to overcome the greatest challenge to breakthrough therapies: The safe and efficient targeting of specific organs and cells.
January 3, 2024
·
2 min read
Biotech Beach
Turn Therapeutics invites public investment for expansion of flagship wound formula into eczema, toenail fungus
Turn Therapeutics launched its first public investment campaign today to fund clinical trials of its Food and Drug Administration-cleared antimicrobial ointment for two potential new drug indications: moderate to severe eczema and onychomycosis, or toenail fungus.
May 22, 2024
·
3 min read
Biotech Bay
Turn Biotechnologies First to Deliver mRNA into the Dermis Using Proprietary LNPs, with No Distribution to Other Organs
Turn Biotechnologies, a cell rejuvenation developer of novel mRNA medicines for untreatable, age-related conditions, announced it is the first company to safely and specifically deliver mRNA in vivo in the skin without any off-target organ uptake.
November 7, 2023
·
2 min read
Biotech Bay
Turn Biotechnologies Co-Founder to Present at Prestigious ARDD Meeting in Copenhagen
Turn Biotechnologies co-founder Vittorio Sebastiano will share company data during a presentation on the potential of epigenetic reprogramming to increase human longevity during this week’s 10th Aging Research and Drug Discovery Meeting, the world’s largest longevity forum.
August 28, 2023
·
2 min read
Vaccines
Moderna Lays Foundations for Growth, but Can It Turn Strategy Into Execution?
The vaccine maker is competing with well-established rivals in markets that have a mix of demand issues as well as commercial and structural headwinds, as the biotech looks to establish new growth drivers.
August 28, 2024
·
6 min read
·
Nick Paul Taylor
1 of 69,127
Next
